

# National Institute for Health and Care Excellence

4-year surveillance (2016) – [Headaches in over 12s: diagnosis and management](#) (2012) NICE guideline CG150

## Appendix B: stakeholder consultation comments table

Consultation dates: 15 August to 26 August 2016

Do you agree with the proposal not to update the guideline?			
Stakeholder	Overall response	Comments	NICE response
The Migraine Trust	Disagree	<p>1.3.9 - Impact statement - Verum acupuncture is not better than placebo in most of the important outcomes assessed.</p> <p>1.3.20 - consider a course of up to 10 sessions of acupuncture over 5 – 8 weeks according to the person's preference, comorbidities and risk of adverse events. [</p> <p>However, there is no mandate for health professionals to prescribe acupuncture. In practice its availability on the NHS is inconsistent.</p> <p>Inclusion of the option of acupuncture on this evidence is potentially confusing for members of the public and therefore it may be better not to include 1.3.20 in the guideline for migraine</p>	<p>Thank you for your comment. The evidence identified supported current recommendations as it suggested there was a benefit for Verum acupuncture. Therefore there is no evidence to suggest a change in the current recommendation at this time.</p>
Royal College of Paediatrics and Child Health	Disagree	None	<p>Thank you for your comment, unfortunately without further information about why you disagree with the proposal not to update the guideline we are unable to investigate further.</p>
British Acupuncture Council	Agree	<p>We note that the recently updated Cochrane reviews of acupuncture for migraine and for tension headache strengthen the case for it to be a recommended treatment. Hence the British Acupuncture Council supports the continuance of the guideline in its current form with respect to acupuncture.</p>	<p>Thank you for your comment.</p>

		<p>Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev. 2016 Jun 28;(6):CD001218. doi: 10.1002/14651858.CD001218.pub3</p> <p>Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Shin BC, Vickers A, White AR. Acupuncture for the prevention of tension-type headache. Cochrane Database Syst Rev. 2016 Apr 19;4:CD007587. doi: 10.1002/14651858.CD007587.pub2</p>	
Elcena Jeffers Foundation	Nothing selected	Comments on proposal not to update the guideline EJF do not agree there is a great deal of work to do with the living of life and to improve our understanding of how the human body works.	Thank you for your comment, unfortunately without further information as to how this relates to the decision not to update CG150 we are unable to investigate further.
Allergan Ltd	Nothing selected	<p>Allergan disagrees with this proposal. The current guideline makes almost no reference to NICE TAG260 which contains the following recommendation:  Botulinum toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine):  that has not responded to at least three prior pharmacological prophylaxis therapies  and  whose condition is appropriately managed for medication overuse.</p> <p>To mentions in section 1.2 (Diagnosis) that NICE has developed technology appraisal guidance on botulinum toxin type A for the prevention of headaches in adults with chronic migraine but not to include the guidance in section 1.3 (management) implies that either the appraisal was unfavourable or is no longer relevant and can therefore be ignored.</p> <p>Allergan considers that this recommendation falls within the scope of CG150 and that, in the interests of consistency between NICE guidelines and technology appraisal guidance, CG150 should be updated to take account of TAG260. The continuing absence of any reference to NICE's recommendation for botulinum toxin type A in the headache guidelines could be interpreted by some clinical commissioning groups as a signal to disregard TAG260. This would</p>	Thank you for your comment. TA260 is currently linked to within the guideline recommendation 1.2.1 and is available on the NICE website and through the guideline pathway.

deny certain patients the benefit of a recommendation arrived out after a thorough review of cost and clinical effectiveness evidence.

### Do you agree with the proposal to remove the research recommendation:

Is amitriptyline a clinically and cost effective prophylactic treatment for recurrent migraine?

Stakeholder	Overall response	Comments	NICE response
The Migraine Trust	Agree	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	Agree	Amitriptyline is low safety profile and risky, so we agree to remove this research recommendation from the NICE version and research database.	Thank you for your comment.
British Acupuncture Council	None	None	Thank you for your comment.
Elcena Jeffers Foundation	Nothing selected	There is more work to be done.	Thank you for your comment.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

### Do you agree with the proposal to remove the research recommendation:

Is pizotifen a clinically and cost effective prophylactic treatment for recurrent cluster headache?

Stakeholder	Overall response	Comments	NICE response
The Migraine Trust	Agree	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	Disagree	We have been informed that this is quite useful in practice, so disagree to remove this research recommendation from the NICE version and research database.	Thank you for your comment. The 4 year surveillance review did not identify any new evidence relating to this research recommendation. Based on your comment, we will retain this research recommendation.
British Acupuncture Council	None	None	Thank you for your comment.

Elcena Jeffers Foundation	Nothing selected	It is not enough to say there is work to be done, each one of us need to do our bit to make the change. Buy The Money and Buying Back the NHS Project is an Award Winning work base program where everyone can get work that they can do. This is a National Work Program that compliment the Whole System Integrated Care Program.	Thank you for your comment, unfortunately without further information as to how this relates to the research recommendation we are unable to investigate further.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

### Do you agree with the proposal to remove the research recommendation:

Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache?

The Migraine Trust	Agree	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	Agree	We have been informed that this used occasionally and useful, but agree to remove this research recommendation from the NICE version and research database.	Thank you for your comment.
British Acupuncture Council	None	None	Thank you for your comment
Elcena Jeffers Foundation	Nothing selected	Buy The Money and Buying Back the NHS Project is an Award Winning work base program where everyone can get work that they can do. This is a National Work Program that compliment the Whole System Integrated Care Program.	Thank you for your comment, unfortunately without further information as to how this relates to the research recommendation we are unable to investigate further.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

### Do you agree with the proposal to remove the research recommendation:

Does a course of steroid treatment or pharmacological treatments used for headache prophylaxis help people with medication overuse headaches withdraw from medication?

The Migraine Trust	Agree	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	Agree	One of our commenters has stated that a course of steroid treatment or pharmacological treatments used for headache prophylaxis help people with medication overuse headaches withdraw from medication is not helpful, so we agree to remove this research	Thank you for your comment.

		recommendation from the NICE version and research database.	
British Acupuncture Council	None	None	Thank you for your comment.
Elcena Jeffers Foundation	Nothing selected	More work including the National Full-employment.	Thank you for your comment, unfortunately without further information as to how this relates to the research recommendation we are unable to investigate further.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

### Do you have any comments on areas excluded from the scope of the guideline?

Stakeholder	Overall response	Comments	NICE response
The Migraine Trust	No	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	No	None	Thank you for your comment.
British Acupuncture Council	None	None	Thank you for your comment.
Elcena Jeffers Foundation	Nothing selected	People who suffer from headaches can take-up the task of finding solutions to suffering.	Thank you for your comment, unfortunately without further information as to how this area is excluded from the scope of the guideline we are unable to investigate further.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

### Do you have any comments on equalities issues?

Stakeholder	Overall response	Comments	NICE response
-------------	------------------	----------	---------------

The Migraine Trust	No	None	Thank you for your comment.
Royal College of Paediatrics and Child Health	No	None	Thank you for your comment.
British Acupuncture Council	No	None	Thank you for your comment.
Elcena Jeffers Foundation	Nothing selected	People who suffer from headaches can take-up the task of finding solutions to suffering.	Thank you for your comment, unfortunately without further information as to how this impacts equality issues we are unable to investigate further.
Allergan Ltd	Nothing selected	None	Thank you for your comment.

#### Other

Members of NHS England have no comments for the NICE Guideline: **CG150 Headaches in over 12's consultation.** – Thank you for your comment.

Members of the Royal College of Nursing have no comments for the NICE Guideline: **CG150 Headaches in over 12's consultation.** – Thank you for your comment.